Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes

Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog(®); Ly-Lis). Two randomized, controlled, open-label, parallel-group, phase 3 studies were conducted to compare the efficacy and safety of SAR-Lis and Ly-Lis, both in combination with insulin glargine (Lantus(®))....

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Diabetes Technol Ther
Main Authors: Home, Philip, Derwahl, Karl-Michael, Ziemen, Monika, Wernicke-Panten, Karin, Pierre, Suzanne, Kirchhein, Yvonne, Garg, Satish K.
Formáid: Artigo
Teanga:Inglês
Foilsithe: Mary Ann Liebert, Inc. 2018
Ábhair:
Original Articles
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771536/
https://ncbi.nlm.nih.gov/pubmed/29355435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2017.0373
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla